Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

<p>Supplementary Figure 2: Molecular features of A2.DR1 MHC-humanized gliomas. A. Verification of the CRISPR-Cas9-mediated functional KO of p53 and Nf1 in the A2.DR1 glioma cell line. B. Copy number variations (CNVs) in the A2.DR1 glioma cell line. C. Chromosomal distribution of CNVs D. Repres...

保存先:

書誌詳細
第一著者:	Michael Kilian (16697663) (author)
その他の著者:	Mirco Friedrich (3721555) (author), Khwab Sanghvi (16697666) (author), Edward Green (3822586) (author), Stefan Pusch (14934437) (author), Daisuke Kawauchi (15115187) (author), Martin Löwer (133159) (author), Jana K. Sonner (16697669) (author), Christopher Krämer (16697672) (author), Julia Zaman (16697675) (author), Stefanie Jung (554730) (author), Michael O. Breckwoldt (16697678) (author), Gerald Willimsky (16697681) (author), Stefan B. Eichmüller (16697684) (author), Andreas von Deimling (15037904) (author), Wolfgang Wick (15018168) (author), Felix Sahm (15097382) (author), Michael Platten (15018165) (author), Lukas Bunse (16697687) (author)
出版事項:	2025
主題:	Cancer Immuno-oncology CNS Cancers Gliomas, Glioblastomas Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
著者:: Michael Kilian (16697663)
出版事項: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
著者:: Michael Kilian (16697663)
出版事項: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
著者:: Jitske van den Bulk (17142147)
出版事項: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
著者:: Jitske van den Bulk (17142147)
出版事項: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
著者:: Jitske van den Bulk (17142147)
出版事項: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
著者:: Jitske van den Bulk (17142147)
出版事項: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
著者:: Jitske van den Bulk (17142147)
出版事項: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
著者:: Maria Lozano-Rabella (15056515)
出版事項: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
著者:: Maria Lozano-Rabella (15056515)
出版事項: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
著者:: Maria Lozano-Rabella (15056515)
出版事項: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
著者:: Isha Mondal (16721699)
出版事項: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
著者:: Francesca Orzan (15055579)
出版事項: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
著者:: Francesca Orzan (15055579)
出版事項: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
著者:: Francesca Orzan (15055579)
出版事項: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
著者:: Mengjie Zhao (14845174)
出版事項: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
著者:: Mengjie Zhao (14845174)
出版事項: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
著者:: Mengjie Zhao (14845174)
出版事項: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
著者:: Mengjie Zhao (14845174)
出版事項: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
著者:: Mengjie Zhao (14845174)
出版事項: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
著者:: Min Wu (14962986)
出版事項: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
著者:: Min Wu (14962986)
出版事項: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
著者:: Min Wu (14962986)
出版事項: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
著者:: Min Wu (14962986)
出版事項: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
著者:: Sied Kebir (15048732)
出版事項: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
著者:: Sied Kebir (15048732)
出版事項: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
著者:: Sied Kebir (15048732)
出版事項: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
著者:: Sied Kebir (15048732)
出版事項: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
著者:: Sied Kebir (15048732)
出版事項: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
著者:: Defne Bayik (14961098)
出版事項: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
著者:: Qingsheng Xu (17078830)
出版事項: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
著者:: Qingsheng Xu (17078830)
出版事項: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
著者:: Bachchu Lal (17141949)
出版事項: (2025)

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
著者:: Reza Mirzaei (15306062)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_djffvvdf6426lbqn5lcf62ifnu